News | July 24, 2014

Brainlab Introduces New Concept for Treatment of Multiple Brain Metastases

Automatic brain metastases planning software could transform current treatment paradigms

Brainlab Introduces New Concept for Treatment of Multiple Brain Metastases

July 24, 2014 — Brainlab announced the release of its Elements automatic brain metastases planning software. The new software will simplify stereotactic radiosurgery (SRS) planning for metastatic brain tumors and is the newest addition to the Elements A La Carte software portfolio. It was showcased at the 2014 annual meeting of the American Association of Physicists in Medicine (AAPM) in Austin, Texas. The software is a work in progress and currently not for sale in the United States.

“When a patient develops more than one metastasis in the brain, one of the best treatment options available – radiosurgery – becomes impractical because the treatment time increases at the same rate as the number of metastases,” said Stefan Vilsmeier, president and CEO at Brainlab. “With our new technology, we are poised as a company to shift the treatment paradigm and provide more treatment options and a consistent way to deliver them.”

Brain metastases are the most common type of brain tumors, and the numbers continue to rise due to improved diagnostics and control of the primary disease. Whole-brain radiotherapy (WBRT) is still considered the standard of care; however it has been shown that WBRT can only prevent new tumors arising for a maximum of six months. There is clear recognition that not all patients with brain metastases have equivalently poor survival outcome, and a significant group lives for a longer period of time, prompting the debate regarding whether the patients in at least the best-prognosis category should be treated solely with more aggressive therapies upfront and keep WBRT as an option for later. Brainlab automatic brain metastases planning software brings to market technology that consistently and rapidly generates radiosurgery plans for the efficient treatment of multiple metastases.

“The [software] enables a ‘monitor-unit,’ and time-efficient treatment planning and delivery, while reducing the dose to healthy brain tissue,” said Niko Papanikolaou, Ph.D., chief medical physicist, University of Texas Health Science Center, San Antonio. “This novel approach to the treatment of metastatic brain tumors from Brainlab can potentially benefit several patients that are currently receiving whole-brain radiation. We can now plan and treat metastatic brain cancer, for patients with larger volumes and higher number of metastases without the anticipated association of a decline in neurocognitive function.”

Automatic brain metastases planning automatically selects a group of metastases in such a way that the multileaf collimator (MLC) fits to the shapes of these selected targets without leaving gaps. The algorithm generates an optimized volumetric conformal radiosurgery plan in a matter of minutes after all metastases have been outlined. With this new treatment concept, the software creates an optimized dose distribution no matter if one or ten metastases are being treated.

For more information: www.brainlab.com

Related Content

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. #ASTRO2018 #ASTRO #ASTRO18

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. 

News | Computed Tomography (CT) | October 19, 2018
October 19, 2018 – At the 2018 American Society of...
IBA's Proteus system and proton therapy solutions will be discussed at ASTRO 2018. #ASTRO18 #ASTRO #ASTRO2018
News | Proton Therapy | October 19, 2018
October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and t
IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring
News | Radiation Therapy | October 17, 2018
IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the...
Boston Scientific Closes Acquisition of Augmenix Inc.
News | Prostate Cancer | October 17, 2018
Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel...
Varian Expands Cancer Care Portfolio With Noona Healthcare Acquisition
News | Patient Engagement | October 15, 2018
Varian announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based,...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
Videos | Treatment Planning | October 08, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri